(redirected from ALCL)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia.
Related to ALCL: ACL
Graphic Thesaurus  🔍
Display ON
Animation ON
  • noun

Words related to lymphoma

a neoplasm of lymph tissue that is usually malignant

References in periodicals archive ?
Results: In vitro treatment of ALCL by neurolenin B suppressed NPM/ALK, JunB and PDGF-R[beta] expression, inhibited the growth of ALCL cells late in M phase, and induced apoptosis via caspase 3 without compromising mitochondrial activity (as a measure of general exogenic toxicity).
ALCL is the least common subtype within the nodal subgroup, representing 12% of the PTCL cases worldwide (4, 5).
The FDA recommends that health care professionals consider the possibility of ALCL if a patient has late onset, persistent fluid around the implant (peri-implant seroma).
But based on these data, the FDA believes that women with breast implants may have a very small but increased risk of ALCL," reads the warning.
Previous studies have suggested that ALCL was more common in women with implants.
Benjamin Kim and his associates found 36 cases of non-Hodgkin's lymphoma in women with implants, and 29 (81%) of those lymphomas were ALCL.
The rather broad expression of CD30 in reactive processes and other tumors led many individuals to question whether ALCL was a distinct entity.
2,3) From the late 1980s to the mid 1990s, the association between ALCL and a nonrandom t(2;5)(p23;q35) chromosomal translocation involving the nucleophosmin (NPM) gene and the anaplastic lymphoma kinase (ALK) gene was made.
At the recent 54th American Society of Hematology (ASH) Annual Meeting and Exposition held December 8-11, 2012 in Atlanta, GA, encouraging phase I data were presented from an abstract titled "Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Front-line Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas" (Abstract #60).
ALCL associated with breast implants happens when the fibrous scar called a capsule adjacent to the implant develops the cancerous cells.
In January 2009 brentuximab vedotin received orphan product designations for the treatment of patients with HL or ALCL in the European Union from the Committee for Orphan Medicinal Products (COMP).
Fifteen cases of ALCL involving the breast and associated with breast implants have been reported.
The "Drive Breast Cancer Awareness" campaign started in 2011 when its founder Christina Selter, HerHighway's Editor-in-Chief, was diagnosed with possible ALCL, a rare form of liquid breast cancer.